# Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

Source: https://onco.cc/trials/nct07489066/  
OnCo record `nct07489066` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of PF-08634404 in non-small-cell lung cancer and small-cell lung cancer, run by Pfizer, now recruiting.

## Summary

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC is a phase 2 interventional study registered as NCT07489066 by Pfizer, with 120 participants planned, started 2026-06-30 and due to reach its primary completion in 2028-07-29. Interventions recorded: PF-08634404, Chemotherapy Regimen 1, Chemotherapy Regimen 2. Conditions listed: Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07489066
- Phase: 2
- Setting: AN INTERVENTIONAL, OPEN-LABEL, PHASE 2 STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY OR IN COMBINATION IN ADULT PARTICIPANTS WITH EARLY-STAGE RESECTABLE OR LOCALLY ADVANCED UNRESECTABLE NON-SMALL CELL LUNG CANCER
- Sponsor: Pfizer
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT07489066: https://clinicaltrials.gov/study/NCT07489066

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [PF-08634404](https://onco.cc/drugs/pf-08634404/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct07489066.json